Chimeric antigen receptor (CAR) T-cell therapies, best known for its cancer-treating abilities, are being explored as an option for managing autoimmune rheumatic diseases. A team of investigators, including Saira Sheikh, MD, published a guide in ACR Open Rheumatology, providing a detailed exploration of the framework required for rheumatologists to initiate and successfully manage CAR T-cell clinical trials, specifically for systemic lupus erythematosus (SLE).
The team concluded that implementing CAR T-cell therapy trials for SLE involves complex logistical, clinical, and ethical considerations, noting a structured, multidisciplinary, collaborative approach is essential for successful outcomes. By adhering to the comprehensive guide, rheumatologists can effectively initiate and manage cellular therapy clinical trials, optimizing therapeutic options and benefits for patients and advancing the field of rheumatology.
Dr. Sheikh is the Linda Coley Sewell Distinguished Professor of Medicine in the UNC Division of Rheumatology, Allergy and Immunology. She also participated in a Q&A regarding the clinical triall development.
Read the full guide here.
Read the Q&A associated with the guide here.